Compare Peptides

Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.

Popular comparisons

Teriparatide

Forteo, PTH 1-34

FDA Approved
Bone & Metabolic

Collagen Peptides

Hydrolyzed Collagen, Collagen Hydrolysate

Unregulated
Structural & Skin
Overview

A recombinant fragment of parathyroid hormone (amino acids 1-34) FDA-approved for osteoporosis. The first anabolic (bone-building) agent approved for osteoporosis, as opposed to anti-resorptive drugs that only slow bone loss.

Bioactive peptide fragments derived from hydrolyzed collagen protein. The most commercially successful peptide supplement category, with a global market exceeding $5 billion. Available in Types I, II, III, and marine-sourced variants.

Mechanism of Action

Intermittent exposure to PTH(1-34) paradoxically stimulates osteoblast activity more than osteoclast activity, resulting in net bone formation. This is opposite to the bone-resorbing effect of continuously elevated PTH in hyperparathyroidism.

Provides bioavailable proline, glycine, and hydroxyproline — amino acids critical for collagen synthesis. Dipeptides (Pro-Hyp, Hyp-Gly) are absorbed intact and stimulate fibroblast activity, promoting endogenous collagen production in skin, joints, and connective tissue.

Common Uses
  • Severe osteoporosis
  • Fracture risk reduction
  • Glucocorticoid-induced osteoporosis
  • Bone healing acceleration
  • Skin elasticity and hydration
  • Joint health and mobility
  • Hair and nail strength
  • Gut lining support
  • Bone density support
Known Risks
  • Osteosarcoma risk (boxed warning — based on rat studies at high doses)
  • Hypercalcemia
  • Orthostatic hypotension
  • Leg cramps
  • Nausea
  • Limited to 2 years of use
  • Generally well-tolerated
  • Mild GI discomfort in some users
  • Allergic reactions (rare, especially marine-sourced)
  • Heavy metal contamination risk in low-quality products
  • Efficacy debated — some studies industry-funded
Regulatory Status
FDA Approved

FDA-approved as Forteo (2002) for osteoporosis in postmenopausal women and men at high fracture risk. Limited to 2 years of treatment due to theoretical osteosarcoma risk. Biosimilar (Tymlos/abaloparatide is a related but distinct peptide).

Unregulated

Classified as a dietary supplement under DSHEA. Not FDA-approved for any medical indication. Widely available OTC without prescription. No regulatory restrictions.

This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.